Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder
Sponsor: Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Summary
This clinical trial aims to evaluate the safety and preliminary efficacy of intravenous administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs) in patients with autism spectrum disorder (ASD).
Official title: Intravenous Injection of Human Bone Marrow Mesenchymal Stem Cell (hBMMSC) in the Treatment of Autism Spectrum Disorder (ASD): An Exploratory Study on the Safety and Preliminary Efficacy
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
42
Start Date
2025-09-30
Completion Date
2028-08-30
Last Updated
2025-09-17
Healthy Volunteers
No
Conditions
Interventions
hBMMSC
Group 1: 0.5×10\^6 cells/kg (participant's body weight) single dose; Group 2: 1.0×10\^6 cells/kg (participant's body weight) single dose; Group 3: 2.0×10\^6 cells/kg (participant's body weight) single dose.